903 related articles for article (PubMed ID: 26339135)
1. Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments.
de Mattos BR; Garcia MP; Nogueira JB; Paiatto LN; Albuquerque CG; Souza CL; Fernandes LG; Tamashiro WM; Simioni PU
Mediators Inflamm; 2015; 2015():493012. PubMed ID: 26339135
[TBL] [Abstract][Full Text] [Related]
2. Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies.
Ahluwalia B; Moraes L; Magnusson MK; Öhman L
Scand J Gastroenterol; 2018 Apr; 53(4):379-389. PubMed ID: 29523023
[TBL] [Abstract][Full Text] [Related]
3. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
[TBL] [Abstract][Full Text] [Related]
4. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
Burisch J
Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
[TBL] [Abstract][Full Text] [Related]
5. Biologic therapies against inflammatory bowel disease: a dysregulated immune system and the cross talk with gastrointestinal mucosa hold the key.
Dharmani P; Chadee K
Curr Mol Pharmacol; 2008 Nov; 1(3):195-212. PubMed ID: 20021434
[TBL] [Abstract][Full Text] [Related]
6. [Chronic inflammatory bowel disease: Crohn's disease and ulcerative colitis].
Fiasse R; Denis MA; Dewit O
J Pharm Belg; 2010 Mar; (1):1-9. PubMed ID: 20432590
[TBL] [Abstract][Full Text] [Related]
7. Analysis of Safety, Medical Resource Utilization, and Treatment Costs by Drug Class for Management of Inflammatory Bowel Disease in the United States Based on Insurance Claims Data.
Long GH; Tatro AR; Oh YS; Reddy SR; Ananthakrishnan AN
Adv Ther; 2019 Nov; 36(11):3079-3095. PubMed ID: 31562607
[TBL] [Abstract][Full Text] [Related]
8. New strategies in the management of inflammatory bowel disease.
Rutgeerts P; Baert F
Acta Clin Belg; 1999 Oct; 54(5):274-80. PubMed ID: 10555385
[TBL] [Abstract][Full Text] [Related]
9. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
10. Immunosuppressive therapies for inflammatory bowel disease.
Zenlea T; Peppercorn MA
World J Gastroenterol; 2014 Mar; 20(12):3146-52. PubMed ID: 24696600
[TBL] [Abstract][Full Text] [Related]
11. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
Hanauer SB
Gut; 2007 Sep; 56(9):1181-3. PubMed ID: 17698862
[TBL] [Abstract][Full Text] [Related]
12. Application of Drug Repurposing Approach for Therapeutic Intervention of Inflammatory Bowel Disease.
Bhat MA; Usman I; Dhaneshwar S
Curr Rev Clin Exp Pharmacol; 2024; 19(3):234-249. PubMed ID: 37859409
[TBL] [Abstract][Full Text] [Related]
13. New therapies for inflammatory bowel disease: from the bench to the bedside.
Danese S
Gut; 2012 Jun; 61(6):918-32. PubMed ID: 22115827
[TBL] [Abstract][Full Text] [Related]
14. Insights in immunomodulatory therapies for ulcerative colitis and Crohn's disease.
Nguyen GC; Harris ML; Dassopoulos T
Curr Gastroenterol Rep; 2006 Dec; 8(6):499-505. PubMed ID: 17105689
[TBL] [Abstract][Full Text] [Related]
15. CD4+ immune response as a potential biomarker of patient reported inflammatory bowel disease (IBD) activity.
Brandhorst G; Weigand S; Eberle C; Raddatz D; Karaus M; Oellerich M; Walson PD
Clin Chim Acta; 2013 Jun; 421():31-3. PubMed ID: 23485644
[TBL] [Abstract][Full Text] [Related]
16. Emerging immunological targets in inflammatory bowel disease.
Monteleone G; Pallone F; MacDonald TT
Curr Opin Pharmacol; 2011 Dec; 11(6):640-5. PubMed ID: 22000933
[TBL] [Abstract][Full Text] [Related]
17. Classical and recent advances in the treatment of inflammatory bowel diseases.
Sales-Campos H; Basso PJ; Alves VB; Fonseca MT; Bonfá G; Nardini V; Cardoso CR
Braz J Med Biol Res; 2015 Feb; 48(2):96-107. PubMed ID: 25466162
[TBL] [Abstract][Full Text] [Related]
18. Introduction and overview: recent advances in the immunotherapy of inflammatory bowel disease.
Hibi T; Inoue N; Ogata H; Naganuma M
J Gastroenterol; 2003 Mar; 38 Suppl 15():36-42. PubMed ID: 12698869
[TBL] [Abstract][Full Text] [Related]
19. Clinical status, psychosocial impairments, medical treatment and health care costs for patients with inflammatory bowel disease (IBD) in Germany: an online IBD registry.
Bokemeyer B; Hardt J; Hüppe D; Prenzler A; Conrad S; Düffelmeyer M; Hartmann P; Hoffstadt M; Klugmann T; Schmidt C; Weismüller J; Mittendorf T; Raspe H
J Crohns Colitis; 2013 Jun; 7(5):355-68. PubMed ID: 22503168
[TBL] [Abstract][Full Text] [Related]
20. Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases.
Li Y; Chen J; Bolinger AA; Chen H; Liu Z; Cong Y; Brasier AR; Pinchuk IV; Tian B; Zhou J
Inflamm Bowel Dis; 2021 Nov; 27(Suppl 2):S38-S62. PubMed ID: 34791293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
